Pantheon Vision and Eyedeal Medical enter collaborative agreement to develop bioengineered corneal implant

News
Article

Pantheon Vision’s bioengineered corneal implant aims to tackle issues with the success rate of human donated tissue.

Two scientists conversing in a lab Image credit: AdobeStock/peopleimages.com

Image credit: AdobeStock/peopleimages.com

Pantheon Vision has entered into a collaboration agreement with manufacturer Eyedeal Medical to advance the production and commercialization of Pantheon Vision’s bioengineered corneal implant.

At the beginning of 2025, Pantheon completed its third meeting with the US Food and Drug Administration (FDA) review team, after previously completing 2 pre-submission meetings with the organization. The meetings were for guidance on the initial stages of pre-clinical and clinical work supporting a Premarket Approval (PMA) submission for the company’s bioengineered corneal implants to eliminate corneal blindness.

Guo Guangxu, founder and CEO of Eyedeal Medical, and John Sheets, Jr, PhD, president and CEO of Pantheon Vision commented on the partnership in a press release from Pantheon.

“Pantheon Vision has assembled a world-leading ophthalmic design team whose groundbreaking mindset has enabled the bold development of a revolutionary single-piece polymer artificial cornea for vision restoration,” said Guangxu. “This innovation, upon commercialization, will fundamentally eliminate the need for corneal donations while bringing new hope to global patients requiring corneal transplantation."

“This agreement is a critical step for Pantheon Vision as we advance our mission of developing a bioengineered corneal solution to treat and restore vision for people around the world,” said Sheets Jr “We are grateful for the partnership with Eyedeal Medical and are extremely optimistic that together we can create an innovative solution that will provide meaningful benefits to patients suffering from corneal blindness.”

Human donated tissue has less than a 50% success rate at 5 years, among other issues such as short shelf life and insufficient tissue available. The company aims to tackle these issues with its bioengineered corneal implants.

References:
  1. Pantheon Vision signs collaboration agreement with Eyedeal Medical to develop bioengineered corneal implant. Published March 27, 2025. Accessed March 27, 2025. https://www.businesswire.com/news/home/20250327308058/en/Pantheon-Vision-Signs-Collaboration-Agreement-with-Eyedeal-Medical-to-Develop-Bioengineered-Corneal-Implant

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
Steven Greenstein, MD, one of the cochairs of the Collaborative Care Symposium gave some insight into the upcoming conference and what attendees can expect.
Susana Marcos, PhD, discusses the implications her research presents for the role optical coherence tomography (OCT) could play in presbyopia and myopia accommodation efforts.
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
At CIME 2025, Selina McGee, OD, FAAO, says some patients underestimate oculoplastic care. She stands in front of a sign that says Controversies in Modern Eye Care 2025.
Brett Bielory, MD, at ASCRS 2025
© 2025 MJH Life Sciences

All rights reserved.